Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma – OncLive
OncLive |
Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma
OncLive The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) had an objective response rate (ORR) of 76% and a complete response rate (CR) of 47% in patients with aggressive non-Hodgkin lymphoma (NHL) followed for at least 1 month, according … |
